Clinical Situation: Newly Diagnosed

Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

No Prior Therapies

First-line treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

No Prior Therapies

First-line treatment with/without extended (maintenance) treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Overall Survival (months)

The length of time where half the patients in the study are still alive

No Prior Therapies

Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Drug Class Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in NCCN Guidelines
Chemotherapy NCT00426257; OVHIPEC-1 III Carboplatin, HIPEC, Paclitaxel Phase III Randomised Clinical Trial for Stage III Ovarian Carcinoma Randomising Between Secondary Debulking Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy

Among patients with stage III OC, the addition of HIPEC to interval cytoreductive surgery resulted in longer RFS and OS than surgery alone and did not show higher rates of side effects

CarboPt+Pac+HIPEC vs CarboPt+Pac+Placebo:

RFS: 14.3 vs 10.7 months*
OS: 44.9 vs 33.3 months*

pub 2018, 2023

Drugs in Clinical Development
Signaling Pathway Inhibitors: PI3K-AKT-mTOR/mTOR NCT01579812 II Carboplatin, Metformin, Paclitaxel A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Metformin treatment before surgery and added to first-line chemotherapy is well tolerated and is associated with a better than expected OS, particularly in patients with stage II-III disease

PFS: 18.0 months
OS: 57.9 months

pub 2020

Cell Cycle Inhibitors: CDK4/6 NCT03531645 II Abemaciclib, Fulvestrant A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

Neoadjuvant treatment with fulvestrant and abemaciclib is tolerable and demonstrates unprecedented response and complete gross resection rates in Low Grade Serous OC

ORR: 60% (n=15)
DCR: 100%

7 patients w/ IDS:
100% achieved optimal cytoreduction at IDS
(71% R0, 29% R1)

abs Jun 2022 and poster

Immunotherapy: Checkpoint Inhibitors/PD-1 NCT03245892 I Carboplatin, Nivolumab, Paclitaxel A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

In high-risk OC patients, addition of nivolumab to neoadjuvant chemotherapy and as maintenance shows promising PFS and favorable changes in the tumor microenvironment

90% achieved optimal cytoreducation at IDS
(70% R0, 20% R1)
PFS: 15 months
PFS (12 months): 69.6%
Treatment associated w/ significant increase in CD8+ T cells (P = 0.0002)

abs Mar 2020

Immunotherapy: Checkpoint Inhibitors/PD-L1 NCT02726997 I/II Carboplatin, Durvalumab, Paclitaxel Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Durvalumab with chemotherapy in upfront ovarian cancer and continued as maintenance is safe and shows reasonable efficacy

83% obtained optimal cytoreduction at surgery
PFS: 14.5 months

abs Apr 2020

Immunotherapy: Immune Cell Stimulators/IL-12R NCT02480374; OVATION 1 I Carboplatin, IMNN-001, Paclitaxel A Phase I Study of the Safety and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Adding IMNN-001 (GEN-1) IP to carboplatin+paclitaxel is safe, appears to be active in patients receiving neoadjuvant treatment and impacts the tumor microenvironment

ORR at IDS: 85.7% (n=14)
R0 resection rate: 64.3%
PFS: 21 months

pub 2021

*Statistically significant result

First-line treatment

For more detailed information, please click on the clinical trial ID number.

Drug Class Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Standard of Care Chemotherapy
Chemotherapy GOG-158 III Carboplatin, Cisplatin, Paclitaxel Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study.

No PFS or OS difference between cisplatin+paclitaxel and carboplatin+paclitaxel in optimally debulked stage III patients

CisPt+Pac vs CarboPt+Pac:

PFS: 19.4 vs 20.7 months
OS: 48.7 vs 57.4 months

pub 2003

Drugs in NCCN Guidelines
Chemotherapy GOG-172 III Cisplatin, Paclitaxel Randomized phase III study of intravenous (IV) paclitaxel and cisplatin vs. IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172).

PFS and OS increased with IP treatment in optimally debulked stage III patients, but IP had more severe side effects

CisPt+Pac (IV) vs CisPt+Pac (IP):

PFS: 18.3 vs 23.8 months*
OS: 49.7 vs 65.6 months*

pub 2006

Chemotherapy NCT00003998; SCOTROC III Carboplatin, Docetaxel, Paclitaxel A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer

Carboplatin+docetaxel is similar to carboplatin+paclitaxel in terms of response rates and PFS and OS

CarboPt+Pac vs CarboPt+Doc:

ORR: 59.5 vs 58.7%
PFS: 14.8 vs 15.0 months

pub 2014

Chemotherapy NCT00326456; MITO-2 III Carboplatin, Liposomal doxorubicin, Paclitaxel Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer

No significant PFS or OS difference when paclitaxel or liposomal doxorubicin is added to carboplatin, but different toxicity profiles

CarboPt+Pac vs CarboPt+PLD:

PFS: 16.8 vs 19.0 months
OS: 53.2 vs 61.6 months

pub 2011

Chemotherapy NCT01654146; ICON8 III Carboplatin, Paclitaxel An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (ICON8)

No significantly improved PFS with weekly dose-dense chemotherapy compared to standard chemotherapy every 3 weeks

SoC vs CarboPt q3w+Pac qw vs CarboPt+Pac qw:

PFS: 25 vs 25.8 vs 25.9 months
OS: 47.4 vs 54.8 vs 53.4 months

pub 2019, pub 2021, pub 2022

Drugs in Clinical Development
Hormonal Therapy: Aromatase Retrospective Study: Adjuvant Hormone Therapy in LGSC Two sites Letrozole, Tamoxifen, Anastrozole Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival?

Promising PFS and OS in Low Grade Serous Cancer patients treated with letrozole, anastrozole, or tamoxifen following cytoreductive surgery

PFS: Not Reached (41 months follow up)
OS: Not Reached (41 months follow up)

Pub 2017

Signaling Pathway Inhibitors: PI3K-AKT-mTOR/mTOR IRCT2016- 022726788N1 II Carboplatin, Metformin, Paclitaxel Evaluation of the clinical efficacy of adding metformin to chemotherapy regimen for patients with ovarian cancers

Improved RFS with addition of metformin to carboplatin+paclitaxel in stage I-III patients

CarboPt+Pac+Met vs CarboPt+Pac:

RFS: 48.0 vs 25.7 months

pub 2018

*Statistically significant result

First-line treatment with/without extended (maintenance) treatment

For more detailed information, please click on the clinical trial ID number.

Drug Class Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Standard of Care Targeted Drugs
Angiogenesis Inhibitors: VEGF NCT00262847; GOG-218 III Bevacizumab, Carboplatin, Paclitaxel Prescribing Information A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG218)

Improved PFS, but no OS difference with addition of bevacizumab to carboplatin+paclitaxel; potential benefit for patients with stage IV disease

CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac+Bev vs CarboPt+Pac:

All:
PFS: 14.1 vs 11.2 vs 10.3 months*
OS: 43.4 vs 40.8 vs 41.1 months

Stage IV patients:
OS: 42.8 vs 34.5 vs 32.6 months

pub 2019

Angiogenesis Inhibitors: VEGF NCT00483782; ICON7 III Bevacizumab, Carboplatin, Paclitaxel ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer

Improved PFS and OS with addition of bevacizumab to carboplatin+paclitaxel in high risk patients

CarboPt+Pac+Bev w/ Bev maint vs CarboPt+Pac:

All:
PFS: 19.9 vs 17.5 months
OS: 45.5 vs 44.6 months (restricted mean survival)
High risk:
PFS: 16.0 vs 10.5 months*
OS: 39.3 vs 34.5 months* (restricted mean survival)

pub 2011; 2015, 2020

Angiogenesis Inhibitors: VEGF NCT01462890; AGO-OVAR17 III Bevacizumab, Carboplatin, Paclitaxel A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Longer treatment with bevacizumab for up to 30 months improves neither PFS nor OS in patients with newly diagnosed ovarian cancer. Therefore bevacizumab treatment duration of 15 months remains standard of care

PFS: 24.2 vs 26.0 months
OS: 54.3 vs 60.0 months

pub 2023

Drugs in NCCN Guidelines
Chemotherapy NCT01081262; mEOC/GOG-241 III Carboplatin, Oxaliplatin, Paclitaxel, Bevacizumab, Capecitabine A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)

No firm conclusion about best treatment options for mucinous ovarian cancer can be made, however, slight evidence suggests that oxaliplatin/capecitabine should be investigated further

CarboPt+Pac+/-Bev vs Oxa+Cap+/-Bev:

PFS: 16.4 vs 14.2 months
OS: 27.7 vs 33.9 months

Bev vs no Bev:

PFS: 18.1 vs 8.8 months
OS: 27.7 vs 32.7 months

pub 2017

Drugs in Clinical Development
DNA Damage Repair Pathway Inhibitors: PARP NCT02470585; VELIA III Carboplatin, Paclitaxel, Veliparib A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Veliparib added to chemotherapy and continued as maintenance significantly extends PFS in all newly diagnosed patients, but shows most benefit in BRCA MUT patients

CarboPt+Pac+Vel w/Vel maint vs CarboPt+Pac+Vel vs CarboPt+Pac:

All patients:
PFS: 23.5 vs 15.2 vs 17.3 months*
BRCA MUT:
PFS: 34.7 vs 21.1 vs 22.0 months*
BRCA WT:
PFS: 18.2 vs 14.5 vs 15.1 months

pub 2019

DNA Damage Repair Pathway Inhibitors: PARP NCT00989651; GOG-9923 I Carboplatin, Cisplatin, Paclitaxel, Veliparib, Bevacizumab A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Patients receiving IP cisplatin + IV/IP paclitaxel show promising PFS and OS when compared to patients receiving IV carboplatin+paclitaxel, however differences may be reflective of selection bias toward patients enrolled on the IP chemotherapy arm

IV vs weekly IV vs IP (all w/ Vel cont):

PFS: 24.5 vs 23.5 vs 43.2 months
OS: 65.2 vs 66.5 vs NR months

pub 2020, abs Mar 2020

Angiogenesis Inhibitors: VEGF ISRCTN10356387; ICON8B III Bevacizumab, Carboplatin, Paclitaxel ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment

In primary treatment of high-risk stage IIIC/IV ovarian cancer, bevacizumab with weekly taxol and carboplatin improves PFS and OS compared to bevacizumab with standard three weekly chemotherapy

SoC+Bev vs CarboPt q3w+Pac qw+Bev:

PFS: 16.7 vs 22.2 months*
OS: 40.9 vs 51.1 months*

abs Oct 2023

Angiogenesis Inhibitors: VEGF NCT00951496; GOG-252 III Carboplatin, Cisplatin, Paclitaxel, Bevacizumab A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Compared to the IV reference arm, PFS was not significantly increased with either IP regimen

IV CarboPt+Pac+Bev w/ Bev maint vs IP CarboPt+Pac+Bev w/ Bev maint vs IP CisPt+Pac+Bev w/ Bev maint:

PFS: 24.9 vs 27.4 vs 26.2 months
OS: 75.5 vs 78.9 vs 72.9 months

stage II/III disease with no residual disease (R0):
PFS: 35.9 vs 38.8 vs 35.5 months
OS: 108.6 vs 114.2 vs 107.9 months

pub 2019, abs Mar 2022

Immunotherapy: Checkpoint Inhibitors/PD-1 NCT02766582 II Carboplatin, Paclitaxel, Pembrolizumab Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer

Pembrolizumab with carboplatin+paclitaxel on a weekly schedule is overall well tolerated and 12 months PFS is promising

28 patients
PFS (6 months): 82%
PFS (9 months): 77%
PFS (12 months): 59%

abs Mar 2020

Immunotherapy: Checkpoint Inhibitors/PD-L1 NCT02718417; JAVELIN Ovarian 100 III Avelumab, Carboplatin, Paclitaxel A Randomized, Open-Label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (MSB0010718C) In Combination With And/Or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100

Avelumab addition to carboplatin+paclitaxel and/or continued as maintenance therapy for newly diagnosed ovarian cancer patients does not improve PFS; PD-L1, CD8, and gBRCA1/2 status did not predict differential clinical benefit 

CarboPt+Pac+Ave+Ave maint vs CarboPt+Pac+Ave maint vs CarboPt+Pac:

ORR: 36.0 vs 30.4 vs 30.4%
PFS: 18.1 vs 16.8 vs NR months

pub 2021

Immunotherapy: Checkpoint Inhibitors/PD-L1 NCT03038100; IMagyn050 III Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Atezolizumab does not significantly improve PFS or OS in the ITT or PD-L1+ population, but the poor prognostic subgroup of patients (unfavorable KELIM score and sub-optimal surgery), might derive a significant PFS benefit from the treatment intensification with atezolizumab

CarboPt+Pac+Bev+Ate vs CarboPt+Pac+Bev+Placebo:
PFS: 19.5 vs 18.4 months
OS: 50.5 vs 46.6 months

w/ unfavorable KELIM score and sub-optimal surgery:
PFS: 14.3 vs 11.3 months*

pub 2021, 2023, abs Mar 2024

Immunotherapy: Checkpoint Inhibitors/PD-L1 NCT03737643; DUO-O III Bevacizumab, Carboplatin, Durvalumab, Olaparib, Paclitaxel A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

CarboPt+Pac+Bev+Dur followed by maintenance Bev+Dur+Ola in patients with newly diagnosed non-BRCA MUT advanced OC shows a statistically significant and clinically meaningful improvement in PFS vs CarboPt+Pac+Bev followed by maintenance Bev

ITT (excl. tBRCA MUT):
PFS: 25.1 vs 20.6 vs 19.3 months*

HRD+ (excl. tBRCA MUT):
PFS: 45.1 vs 25.1 vs 23.3 months*

HRD-:
PFS: 21.1 vs 15.4 vs 17.5 months*

abs Jun 2023 and presentation, abs Mar 2024

Immunotherapy: Vaccine/TAA NCT02107937; SOVO1 II DCVAC/OvCa A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma

DCVAC/OvCa sequential to chemo is associated with a statistically significant improvement in PFS in patients undergoing first-line treatment

DCVAC sequential to chemo vs chemo alone:
PFS: NR vs 21.4 months*

pub 2022

*Statistically significant result

< Return to Clinical Situation

< Return to Clinical Trial Results Homepage